Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSC Transplantation for Premature Ovarian Failure
NCT02062931Phase 2Unknown
- Start
- Mar 2012
- Primary completion
- May 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in primary ovarian insufficiency (POI). Primary endpoint: Improvement of Cases at 48 weeks. Status: unknown.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT02062931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062931.